Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glyburide
Drug ID BADD_D01030
Description Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].[L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]
Indications and Usage Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.[L8120,L8123]
Marketing Status approved
ATC Code A10BB01
DrugBank ID DB01016
KEGG ID D00336
MeSH ID D005905
PubChem ID 3488
TTD Drug ID D05LYX
NDC Product Code 76333-154; 76333-155; 65691-0041; 23155-058; 0093-8034; 50090-0495; 51655-492; 65841-833; 68071-5217; 68382-658; 71209-011; 72241-039; 12579-056; 62147-0002; 50090-5776; 55700-725; 62135-584; 63187-848; 68071-3452; 70518-1646; 70934-690; 71335-0150; 12828-0066; 0093-8342; 0093-9477; 50090-6196; 62135-583; 62135-585; 68071-2189; 68788-8343; 71335-0069; 71209-009; 49452-3355; 0093-8036; 0093-9364; 53002-4170; 65841-834; 68382-656; 72241-040; 75834-204; 76333-156; 23155-056; 0009-0352; 0009-3449; 63187-659; 65841-832; 70518-3504; 65862-318; 68382-657; 75834-202; 43898-0001; 0093-8344; 0093-9433; 61919-378; 68071-2589; 23155-057; 68788-7970; 70518-1201; 46438-0059; 0009-0341; 63187-667; 70518-1513; 70934-855; 71209-010; 72241-038; 75834-203; 12579-054; 12579-055; 0093-8035; 0093-8343; 51655-659
UNII SX6K58TVWC
Synonyms Glyburide | Glybenclamide | Glibenclamide | Diabeta | Euglucon 5 | Neogluconin | HB-419 | HB 419 | HB419 | HB-420 | HB 420 | HB420 | Maninil | Micronase | Daonil | Euglucon N
Chemical Information
Molecular Formula C23H28ClN3O5S
CAS Registry Number 10238-21-8
SMILES COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash morbilliform23.03.13.005--Not Available
Respiratory arrest22.02.01.0090.000101%Not Available
Screaming19.04.02.020; 08.01.03.099--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Snoring22.12.03.0250.000101%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Suicide attempt19.12.01.0040.000253%
Tachycardia02.03.02.007--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura01.08.01.003; 23.06.01.007--Not Available
Tremor17.01.06.002--
Unresponsive to stimuli17.02.05.0310.000455%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000101%
Urticaria23.04.02.001; 10.01.06.0010.000222%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.0030.000617%
Mental status changes19.07.01.0010.000202%Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000101%
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene